Insider Selling: Edwards Lifesciences (NYSE:EW) VP Sells $87,328.30 in Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Daniel Lippis sold 1,019 shares of the business’s stock in a transaction dated Friday, January 9th. The shares were sold at an average price of $85.70, for a total value of $87,328.30. Following the transaction, the vice president owned 22,002 shares in the company, valued at approximately $1,885,571.40. This represents a 4.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Edwards Lifesciences Trading Up 0.7%

Shares of EW stock traded up $0.56 during trading hours on Friday, reaching $85.14. The company’s stock had a trading volume of 3,383,825 shares, compared to its average volume of 3,634,187. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a one year low of $65.94 and a one year high of $87.89. The stock has a market capitalization of $49.41 billion, a P/E ratio of 36.70, a P/E/G ratio of 3.45 and a beta of 0.95. The firm’s fifty day simple moving average is $85.01 and its 200 day simple moving average is $80.25.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion during the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The firm’s revenue was up 14.7% on a year-over-year basis. During the same quarter last year, the firm posted $0.67 earnings per share. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts expect that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Norges Bank purchased a new position in Edwards Lifesciences in the second quarter worth about $580,640,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its stake in shares of Edwards Lifesciences by 111.2% in the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 9,129,357 shares of the medical research company’s stock worth $714,006,000 after purchasing an additional 4,805,819 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in shares of Edwards Lifesciences by 278.3% in the third quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after buying an additional 4,108,270 shares during the last quarter. Marshall Wace LLP boosted its holdings in shares of Edwards Lifesciences by 127.5% in the second quarter. Marshall Wace LLP now owns 6,895,579 shares of the medical research company’s stock worth $539,303,000 after buying an additional 3,864,908 shares during the last quarter. Finally, Viking Global Investors LP bought a new stake in Edwards Lifesciences during the third quarter valued at approximately $238,688,000. 79.46% of the stock is owned by institutional investors.

Analyst Ratings Changes

EW has been the subject of several research reports. Mizuho increased their price target on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a research note on Friday, October 31st. BTIG Research reiterated a “buy” rating and issued a $103.00 target price (up previously from $100.00) on shares of Edwards Lifesciences in a research note on Thursday, December 4th. Truist Financial set a $92.00 price target on shares of Edwards Lifesciences and gave the company a “hold” rating in a research report on Friday, December 5th. Wells Fargo & Company set a $100.00 price objective on Edwards Lifesciences in a research report on Thursday, December 18th. Finally, Piper Sandler reissued an “overweight” rating and issued a $95.00 target price (up previously from $90.00) on shares of Edwards Lifesciences in a report on Friday, October 31st. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $94.57.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.